GRAIL, Inc., a healthcare company whose mission is to detect cancer early, is now hiring for its new state-of-the-art laboratory facility located in Research Triangle Park (RTP). The company expects to hire more than 100 employees for the site by the end of 2021.
GRAIL’s RTP site, announced by North Carolina Gov. Roy Cooper last summer, is expected to open to employees in the spring and laboratory operations could begin as early as this fall. The 200,000-square-foot state-of-the-art facility in the Park Point Office and Life Science Park will feature office and warehouse space and a campus cafe and gym for employees, who could eventually number in the hundreds.
“Building our RTP team is an important step forward in making our novel multi-cancer early detection blood test widely available to patients and healthcare providers across the country,” said Matthew Young, chief operating officer and chief financial officer at GRAIL. “We are already seeing the benefits of tapping into the large pool of skilled talent and innovative spirit the Triangle offers, and we look forward to growing our team with people who are excited and inspired by our mission to detect cancer early.”
Andrew Crenshaw, a local North Carolinian with more than 20 years of experience in the clinical and biomedical research industry, recently joined GRAIL as vice president of operations and RTP site director.
Hiring is underway for laboratory scientists and technologists; equipment, quality, and automation engineers; and supply chain and warehouse personnel. Candidates are encouraged to visit www.grail.com/careers to view and apply for open positions. A virtual open house is planned for April 27 at noon ET to introduce GRAIL to the community and to view a video of the new facility. To register for the virtual event, please visit this link.
“As a native North Carolinian, it is an honor to be part of GRAIL’s expansion to our great state,” Crenshaw said. “For those passionate about joining a team pursuing a game-changing and potentially life-saving mission, we encourage you to apply for an open role.”
GRAIL expects to introduce Galleri™, its multi-cancer early detection blood test, in the second quarter of this year.